BUSINESS: International News OcuMension Acquires Rights to Alcon Eye Drops in China in Exchange for 16.7 Percent Equity Stake By Staff Friday, August 23, 2024 9:05 AM SHANGHAI—OcuMension Therapeutics, a leading Chinese ophthalmic pharmaceutical platform company, has announced an agreement with Alcon Inc., a leader in eyecare, in which OcuMension has acquired commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. Read More